How Clemmer was paid
$5.5M in total for fiscal Year 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| James C. ClemmerPresident, CEO | $803,027 | $2,628,871 | $808,207 | $1,215,608 | $38,572 | $5,494,285 |
| Stephen A. TrowbridgeEVP, CFO | $455,847 | $934,085 | $287,497 | $449,664 | $34,704 | $2,161,797 |
| Lawrence T. WeissSVP & Chief Legal Officer | $206,731 | $376,257 | $386,656 | $193,500 | $6,923 | $1,170,067 |
| Laura PiccininiSVP & GM, Cardiovascular and International | $410,056 | $414,834 | $112,291 | $371,758 | $60,487 | $1,369,426 |
| Warren G. NighanSVP & GM, Global Supply Chain, Quality and Regulatory Affairs | $401,309 | $337,186 | $88,391 | $303,361 | $34,899 | $1,165,146 |
What changed and why
- $5.5M$5,494,285 CEO total compensation exceeded the $5,005,971 reported for fiscal 2024.
- $1.2M$1,215,608 CEO annual incentive compensation exceeded the $783,000 paid for fiscal 2024.
- $2.6M$2,628,871 in CEO stock awards and $808,207 in option awards were reported for fiscal 2025.
- $124K44:1 was the CEO-to-median-employee pay ratio, based on median employee compensation of $124,242.
- December 2024 hire Lawrence Weiss received prorated salary, incentive compensation and other compensation.
- Fiscal 2025 equity awards included restricted stock units, performance shares and ten-year stock options.
Other Angiodynamics proxy statements
- 2026 proxy statement
James C. Clemmer paid $6.1M (+10% on the year), pay ratio 45:1.
Filed Oct 08, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.